Emerging Biologics in Severe Asthma

被引：11

作者：

Pavord, Ian D. ^{[1
,2
]}

Hilvering, Bart ^{[1
,2
,3
]}

Shrimanker, Rahul ^{[1
,2
]}

机构：

[1] Univ Oxford, Dept Resp Med, Old Rd, Oxford OX3 7LE, England

[2] Univ Oxford, Nuffield Dept Med, Old Rd Campus, Oxford OX3 7FZ, England

[3] Univ Med Ctr, Dept Resp Med, Lab Translat Immunol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

来源：

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2016年 / 36卷 / 03期

关键词：

Severe asthma; Biomarkers; Type-2; cytokines; Anti-IL-5; Anti-IL-13; Anti-IL-4&13; OBSTRUCTIVE PULMONARY-DISEASE; SEVERE EOSINOPHILIC ASTHMA; SEVERE PERSISTENT ASTHMA; PLACEBO-CONTROLLED TRIAL; TO-SEVERE ASTHMA; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; AIRWAY INFLAMMATION; SPUTUM EOSINOPHILIA; CXCR2; ANTAGONIST;

D O I：

10.1016/j.iac.2016.04.001

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Asthma is characterized by typical symptoms, variable airway obstruction and airway inflammation. Most patients with asthma are well controlled when treated with inhaled corticosteroids. However, around 10% have severe asthma, and remain symptomatic and/or at risk of asthma attacks despite maximum inhaled therapy. Identification of eosinophilic airways inflammation is particularly important as biological agents blocking interleukin (IL)-5, IL-13 and both IL-4 and 13 are effective treatments in this sub-group. The future will be identification of potentially responsive patients on the basis of biomarkers rather than arbitrary physiological patterns of disease, and targeted treatment with specific cytokine blockade.

引用

页码：609 / +

页数：16

共 39 条

[11] A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma [J].

Corren, Jonathan ;

Busse, William ;

Meltzer, Eli O. ;

Mansfield, Lyndon ;

Bensch, George ;

Fahrenholz, John ;

Wenzel, Sally E. ;

Chon, Yun ;

Dunn, Meleana ;

Weng, Haoling H. ;

Lin, Shao-Lee .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (08) :788-796

[12] Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial [J].

De Boever, Erika H. ;

Ashman, Claire ;

Cahn, Anthony P. ;

Locantore, Nicholas W. ;

Overend, Phil ;

Pouliquen, Isabelle J. ;

Serone, Adrian P. ;

Wright, Tracey J. ;

Jenkins, Mair M. ;

Panesar, Inderpal S. ;

Thiagarajah, Sivayogan S. ;

Wenzel, Sally E. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (04) :989-+

[13] Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics [J].

Flood-Page, P ;

Menzies-Gow, A ;

Phipps, S ;

Ying, S ;

Wangoo, A ;

Ludwig, MS ;

Barnes, N ;

Robinson, D ;

Kay, AB .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (07) :1029-1036

[14] A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma [J].

Flood-Page, Patrick ;

Swenson, Cheri ;

Faiferman, Isidore ;

Matthews, John ;

Williams, Michael ;

Brannick, Lesley ;

Robinson, Douglas ;

Wenzel, Sally ;

Busse, William ;

Hansel, Trevor T. ;

Barnes, Neil C. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (11) :1062-1071

[15] Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway [J].

Flood-Page, PT ;

Menzies-Gow, AN ;

Kay, AB ;

Robinson, DS .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (02) :199-204

[16] Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma [J].

Gauvreau, Gail M. ;

Boulet, Louis-Philippe ;

Cockcroft, Donald W. ;

FitzGerald, J. Mark ;

Carlsten, Chris ;

Davis, Beth E. ;

Deschesnes, Francine ;

Duong, MyLinh ;

Durn, Billie L. ;

Howie, Karen J. ;

Hui, Linda ;

Kasaian, Marion T. ;

Killian, Kieran J. ;

Strinich, Tara X. ;

Watson, Richard M. ;

Nathalie, Y. ;

Zhou, Simon ;

Raible, Donald ;

O'Byrne, Paul M. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (08) :1007-1014

[17]

GINA guidelines, 2014, 2014 GINA GUID GLOB

[18] Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness [J].

Green, R. H. ;

Brightling, C. E. ;

McKenna, S. ;

Hargadon, B. ;

Neale, N. ;

Parker, D. ;

Ruse, C. ;

Hall, I. P. ;

Pavord, I. D. .

EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (06) :1144-1151

[19] Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial [J].

Green, RH ;

Brightling, CE ;

McKenna, S ;

Hargadon, B ;

Parker, D ;

Bradding, P ;

Wardlaw, AJ ;

Pavord, ID .

LANCET, 2002, 360 (9347) :1715-1721

[20] Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma [J].

Haldar, Pranabashis ;

Brightling, Christopher E. ;

Hargadon, Beverley ;

Gupta, Sumit ;

Monteiro, William ;

Sousa, Ana ;

Marshall, Richard P. ;

Bradding, Peter ;

Green, Ruth H. ;

Wardlaw, Andrew J. ;

Pavord, Ian D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (10) :973-984

← 1 2 3 4 →